We provide you with 20 years of free, institutional-grade data for AVTE stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of AVTE. Explore the full financial landscape of AVTE stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$0
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|---|---|---|---|---|
| Frohlich Tom | Open Market Purchase | 6,000 | $7.4 | 2025-05-19 | |
| Klein Lawrence Otto | Initial | 2025-05-01 | |||
| King Andrew James | Initial | 2025-05-01 | |||
| Dake Benjamin T | Derivatives Exercise | 12,961 | 2024-08-02 | ||
| RA CAPITAL MANAGEMENT, L.P. | Open Market Purchase | 928,110 | $1.67 | 2024-06-20 | |
| Gillies Hunter | Sale | -6,000 | $24.5 | $147,000 | 2024-06-14 |
| Gillies Hunter | Derivatives Exercise | 6,000 | 2024-06-14 | ||
| Verwijs Marinus | Sale | -10,600 | $25 | $265,000 | 2024-06-14 |
| Verwijs Marinus | Derivatives Exercise | 10,600 | 2024-06-14 | ||
| Eldridge George A | Sale | -15,000 | $25.03 | $375,450 | 2024-06-14 |
| Eldridge George A | Derivatives Exercise | 15,000 | 2024-06-14 | ||
| NOYES TIMOTHY P | Sale | -10,000 | $21.52 | $215,241 | 2024-05-17 |
| NOYES TIMOTHY P | Derivatives Exercise | 10,000 | 2024-05-17 | ||
| NOYES TIMOTHY P | Sale | -11,357 | $20.34 | $231,028 | 2024-05-03 |
| NOYES TIMOTHY P | Derivatives Exercise | 10,000 | 2024-05-03 | ||
| Verwijs Marinus | Sale | -1,981 | $21.02 | $41,631 | 2024-05-03 |
| Dake Benjamin T | Sale | -6,853 | $22.32 | $152,925 | 2024-04-19 |
| Dake Benjamin T | Derivatives Exercise | 6,853 | 2024-04-19 | ||
| Gillies Hunter | Sale | -4,000 | $22.3 | $89,202 | 2024-04-19 |
| Gillies Hunter | Derivatives Exercise | 4,000 | 2024-04-19 | ||
| NOYES TIMOTHY P | Sale | -10,000 | $24.4 | $243,956 | 2024-04-18 |
| NOYES TIMOTHY P | Derivatives Exercise | 10,000 | 2024-04-18 | ||
| Eldridge George A | Sale | -7,500 | $26.77 | $200,780 | 2024-04-12 |
| Eldridge George A | Derivatives Exercise | 7,500 | 2024-04-12 | ||
| GRAYZEL DAVID S. | Sale | -11,882 | $28.15 | $334,478 | 2024-04-11 |
| Eldridge George A | Sale | -12,495 | $31.23 | $390,208 | 2024-04-03 |
| Eldridge George A | Derivatives Exercise | 12,495 | 2024-04-03 | ||
| Verwijs Marinus | Sale | -5,300 | $28.87 | $152,995 | 2024-04-03 |
| Verwijs Marinus | Derivatives Exercise | 5,300 | 2024-04-03 | ||
| Dake Benjamin T | Sale | -3,325 | $31.97 | $106,317 | 2024-04-03 |
| Dake Benjamin T | Derivatives Exercise | 3,325 | 2024-04-03 | ||
| NOYES TIMOTHY P | Sale | -10,000 | $28.96 | $289,647 | 2024-04-03 |
| NOYES TIMOTHY P | Derivatives Exercise | 10,000 | 2024-04-03 | ||
| Gillies Hunter | Sale | -9,000 | $29.5 | $265,500 | 2024-04-01 |
| Gillies Hunter | Derivatives Exercise | 9,000 | 2024-04-01 | ||
| Dake Benjamin T | Sale | -11,068 | $27.97 | $309,519 | 2024-03-28 |
| Dake Benjamin T | Derivatives Exercise | 11,068 | 2024-03-28 | ||
| Dake Benjamin T | Sale | -3,432 | $28.01 | $96,119 | 2024-03-27 |
| Dake Benjamin T | Derivatives Exercise | 3,432 | 2024-03-27 | ||
| Gillies Hunter | Sale | -7,000 | $25.81 | $180,696 | 2024-03-20 |
| Gillies Hunter | Derivatives Exercise | 7,000 | 2024-03-20 | ||
| Verwijs Marinus | Sale | -5,300 | $25.68 | $136,093 | 2024-03-20 |
| Verwijs Marinus | Derivatives Exercise | 5,300 | 2024-03-20 | ||
| Dake Benjamin T | Sale | -35,057 | $25.74 | $902,430 | 2024-03-20 |
| Dake Benjamin T | Derivatives Exercise | 35,057 | 2024-03-20 | ||
| Eldridge George A | Sale | -4,067 | $25.05 | $101,862 | 2024-03-14 |
| Eldridge George A | Derivatives Exercise | 4,067 | 2024-03-14 | ||
| Gillies Hunter | Sale | -8,975 | $24.5 | $219,888 | 2024-03-11 |
| Gillies Hunter | Derivatives Exercise | 8,975 | 2024-03-11 | ||
| Eldridge George A | Sale | -25,933 | $25 | $648,369 | 2024-03-11 |
| Eldridge George A | Derivatives Exercise | 25,933 | 2024-03-11 | ||
| Gillies Hunter | Sale | -511 | $19.5 | $9,965 | 2024-02-27 |
| Gillies Hunter | Derivatives Exercise | 511 | 2024-02-27 | ||
| Gillies Hunter | Sale | -3,489 | $20.11 | $70,153 | 2024-02-22 |
| Gillies Hunter | Derivatives Exercise | 3,489 | 2024-02-22 | ||
| NIVEN RALPH | Sale | -4,600 | $17.45 | $80,249 | 2024-02-07 |
| NIVEN RALPH | Derivatives Exercise | 4,600 | 2024-02-07 | ||
| Gillies Hunter | Sale | -4,000 | $19.5 | $78,000 | 2024-01-19 |
| Gillies Hunter | Derivatives Exercise | 4,000 | 2024-01-19 | ||
| NIVEN RALPH | Sale | -4,600 | $18.67 | $85,888 | 2024-01-08 |
| NIVEN RALPH | Derivatives Exercise | 4,600 | 2024-01-08 | ||
| Gillies Hunter | Sale | -125 | $24.5 | $3,063 | 2023-12-29 |
| Gillies Hunter | Derivatives Exercise | 125 | 2023-12-29 | ||
| Gillies Hunter | Sale | -4,000 | $19.5 | $78,000 | 2023-12-22 |
| Gillies Hunter | Derivatives Exercise | 4,000 | 2023-12-22 | ||
| Gillies Hunter | Sale | -12,000 | $19.5 | $234,000 | 2023-12-15 |
| Gillies Hunter | Derivatives Exercise | 12,000 | 2023-12-15 | ||
| Dake Benjamin T | Sale | -10,283 | $16.11 | $165,628 | 2023-12-07 |
| Dake Benjamin T | Derivatives Exercise | 10,283 | 2023-12-07 | ||
| NIVEN RALPH | Sale | -4,600 | $16.3 | $74,996 | 2023-12-07 |
| NIVEN RALPH | Derivatives Exercise | 4,600 | 2023-12-07 | ||
| Dake Benjamin T | Sale | -12,517 | $16.24 | $203,237 | 2023-11-29 |
| Dake Benjamin T | Derivatives Exercise | 12,517 | 2023-11-29 | ||
| NIVEN RALPH | Sale | -13,800 | $15 | $207,000 | 2023-11-27 |
| NIVEN RALPH | Derivatives Exercise | 13,800 | 2023-11-27 | ||
| Dake Benjamin T | Sale | -14,372 | $15.17 | $218,075 | 2023-11-27 |
| Dake Benjamin T | Derivatives Exercise | 14,372 | 2023-11-27 |
The information provided in this report about AVTE stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Aerovate Therapeutics Inc(NASDAQ:AVTE) 
Aerovate Therapeutics is a clinical stage biopharmaceutical company whose mission is to advance novel therapeutics and to help people with rare cardiopulmonary diseases gain control over their health, and their lives.
Website: https://www.aerovatetx.com/
Founded: 2018
IPO Price: $14 (Jun 29, 2021)
CEO: Tim Noyes
Sector:
Industry: